| Pharmaceutical Information |
| Drug Name |
Buserelin acetate |
| Drug ID |
BADD_D00315 |
| Description |
Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment. |
| Indications and Usage |
Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. |
| Marketing Status |
approved; investigational |
| ATC Code |
L02AE01 |
| DrugBank ID |
DB06719
|
| KEGG ID |
D01831
|
| MeSH ID |
D002064
|
| PubChem ID |
50224
|
| TTD Drug ID |
D04GSY
|
| NDC Product Code |
71052-358 |
| UNII |
13U86G7YSP
|
| Synonyms |
Buserelin | Buserelin Acetate | Acetate, Buserelin | Suprefact | Profact | Receptal | Tiloryth | Suprecur | Bigonist | HOE-766 | HOE 766 | HOE766 |
|
| Chemical Information |
| Molecular Formula |
C62H90N16O15 |
| CAS Registry Number |
68630-75-1 |
| SMILES |
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=C
C=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(
=O)N6.CC(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
